 BEIJING--BUSINESS WIRE--Sinovac Biotech Ltd. NASDAQ: SVA Sinovac or the Company, a leading provider of biopharmaceutical products in China, today announced that it has officially filed for conditional market authorization for CoronaVac, the COVID-19 vaccine, with Chinas National Medical Products Administration NMPA. The vaccine candidate was tested in phase III clinical studies outside of China. The preliminary results of the trials demonstrated a good safety profile for the vaccin 